Clonal Hematopoiesis and NETs Formation in Venous Thrombosis (CLODETTE)

Venous Thromboses Clinical Trial

— CLODETTE  

Official title:

Role of Clonal Hematopoiesis and NETs Formation in Unusual Venous Thrombosis (CLODETTE)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05711173
• Other study ID #: CHUBX 2022/32
• Status: Recruiting
• Phase: N/A
• Start date: March 3, 2023
• Est. completion date: March 2025

Study information

• Verified date: May 2024
• Source: University Hospital, Bordeaux
• Contact: Alexandre GUY
• Phone: 0557656478
• Email: alexandre.guy[@]chu-bordeaux.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Thrombo-embolic venous diseases are represented by deep venous thrombosis and/or pulmonary embolism. In some patients with repeated thrombosis or occurrence of thrombosis in unusual sites, the etiological workup remains negative, which represents a problem for the management of the anticoagulant treatments. Recently, two factors have been identified as important in the physiopathology of hemostasis and coagulation: the presence of clonal hematopoiesis of indetermined potential (CHIP) and the formation of neutrophil extracellular traps (NETs). In this study, these two factors will be studied in patients with repeated venous thrombosis or thrombosis occurring in unusual site.

Description:

It has recently been shown that some patients clonal have mutations at a low level in hematopoietic cells (this phenomenon is named clonal hematopoiesis of indetermined potential (CHIP)) and that the presence of a clonal hematopoiesis is associated with an increased cardiovascular risk. However, few data exist about the implication of CHIP in venous thrombosis. Neutrophils extracellular traps are involved in the activation of hemostasis and coagulation. Murine models have highlighted the crucial role of NETs in the physiopathology of venous thrombosis. In patients, studies have demonstrated that NETs markers were present in arteries lesions as coronary plaques. However, few studies have analyzed the NETosis in the setting of venous thrombosis.

The study hypothesis is that patients with venous thrombosis may have an increased prevalence of CHIP and/or an increased NETosis formation, which may represent a predisposition for the occurrence of venous thrombosis. We also speculate that patients with CHIP may have an increased NETosis, due to the presence of activating clonal mutations in neutrophils.

Patients included will be : younger than 50-years-old with repeated thrombosis or thrombosis of unusual sites (cerebral venous thrombosis, splanchnic thrombosis) with a negative etiological workup and notably the absence of constitutional or acquired venous thrombosis risk factors. In this population, we will analyze the prevalence of CHIP and the NETosis via the study of 4 different NETosis plasmatic markers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 150
• Est. completion date: March 2025
• Est. primary completion date: March 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 50 Years

Eligibility

Inclusion Criteria:

• Patients (male or female) less than 50 y.o with :

• Splanchnic venous territory thrombosis or

• Cerebral venous thrombosis or

• Venous thrombosis of the upper limb or

• Pulmonary embolism (1st episode if male, 2nd episode if female) unprovoked or

• 1 episode of deep vein thrombosis + 1 episode of arterial thrombosis

Exclusion Criteria:

• Presence of a major or minor transient venous thrombosis risk factor:

• Surgery within the last 3 months preceding the qualifying thrombotic episode

• Lower limb fracture with immobilization > 3 days in the last 3 months preceding the qualifying thrombotic episode

• Presence of estro-progestational contraception

• Pregnancy

• Immobilization for acute medical reasons within the last 3 months preceding the qualifying thrombotic episode

• Air or car travel > 6 hours

• Presence of a major or minor persistent risk factor for venous thrombosis:

• Presence of active cancer (solid cancer or hematologic malignancy)

• Chronic inflammatory digestive or joint diseases

• Ongoing treatment with heparin (low molecular weight heparin (LMWH) or unfractionated heparin (UFH))

• Presence of an abnormality on the thrombophilia test among the following abnormalities

• Protein C deficiency

• Protein S deficiency

• Anti-thrombin deficiency

• Heterozygous or homozygous factor II mutation

• Heterozygous or homozygous factor V mutation

• Presence of anti-phospholipid syndrome

• Presence of myeloproliferative neoplasia

• Presence of paroxysmal nocturnal hemoglobinuria

Related Conditions & MeSH terms

• Clonal Hematopoiesis of Indeterminate Potential
• Neutrophil Extracellular Trap Formation
• Thromboembolic Disease
• Thromboembolism
• Thrombosis
• Venous Thromboses
• Venous Thrombosis

Intervention

Biological:
• Additional blood sampling
The procedure will consist of an additional blood sample for ETDA tube collection (NGS analysis) and citrate tube collection (NETose analysis)

Locations

Country	Name	City	State
France	CHU de Bordeaux, Service de Neurologie	Bordeaux
France	CHU de Bordeaux, Service Gastro-Entérologie	Bordeaux
France	CHU de Bordeaux, Service Hématologie Biologique	Bordeaux
France	CHU de Bordeaux, Service Médecine Vasculaire	Bordeaux
France	CHU de Bordeaux, Unité ambulatoire de Médecine Vasculaire	Bordeaux
France	CHU de Lille, Service Hémostase Clinique	Lille
France	APHM - Hôpital de la Timone, Service Hématologie	Marseille

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Presence of clonal hematopoiesis	The existence of clonal hematopoiesis will be defined as the demonstration of at least one mutation in the blood cells of an apparently healthy subject (without obvious hematological pathology). DNA will be extracted from circulating leukocytes to search for mutations in a panel of 59 genes	At baseline
Secondary	Presence of one or more increased NETosis markers and/or a decreased NETosis-inhibiting marker (DNAse level) compared to a control population.	Analysis of the following markers: MPO-DNA complex, Histone 3-DNA complex, citrullinated histone 3, DNAse	At baseline
Secondary	Correlation (correlation coefficient values) between the presence of a CHIP and the formation of NETs	Correlation analysis will be performed between each NETosis marker and CHIP evaluation (presence or absence, number of mutations, variant allele frequency for each mutation)	During final analysis
Secondary	Allele frequency	Variant allele frequency of each detected mutation will be determined using NGS analysis	At baseline
Secondary	Number of clonal mutations	The number of clonal mutations for each patient will be determined using NGS analysis	At baseline
Secondary	C-reactive protein (CRP) level as a marker of inflammation	C-reactive protein concentration will be determined for each patient, as a marker of inflammation	At baseline
Secondary	Site(s) of thrombosis	Site(s) of thrombosis will be determined during examination of the patient	At baseline
Secondary	Number of thrombosis	The number of thrombosis will be determined during examination of the patient	At baseline